As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...